Involvement of 5-HT7 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents

Neuropharmacology

Volumn 89, Issue , 2015, Pages 382-390

  Westrich, Ligia ^a,d   Haddjeri, Nasser ^b,c   Dkhissi Benyahya, Ouria ^b,c   Sánchez, Connie ^a  

^a LUNDBECK RESEARCH USA   (United States)

^b STEM CELL AND BRAIN RESEARCH INSTITUTE   (France)

^c UNIVERSITÉ DE LYON   (France)

^d FAIRLEIGH DICKINSON UNIVERSITY   (United States)

Author keywords

5 HT7 receptor; Behavior; Biological rhythms; Episodic memory; Serotonin; Suprachiasmatic nucleus; Vortioxetine

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; AS 19; FLESINOXAN; LUCIFERASE; PER2 PROTEIN; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; UNCLASSIFIED DRUG; VORTIOXETINE; CIRCADIAN RHYTHM SIGNALING PROTEIN; PER2 PROTEIN, MOUSE; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CIRCADIAN RHYTHM; CONTROLLED STUDY; EPISODIC MEMORY; LOCOMOTION; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROTEIN EXPRESSION; RAT; RUNNING; SUPRACHIASMATIC NUCLEUS; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; GENETICS; MEMORY; METABOLISM; MOTOR ACTIVITY; RECOGNITION; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ANIMALS; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MEMORY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PERIOD CIRCADIAN PROTEINS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECOGNITION (PSYCHOLOGY); SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SULFIDES;

EID: 84918502348     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.10.015     Document Type: Article

References (47)

1. Adell, A., 2010. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs 13, 900-910.
2. Adriani, W., Travaglini, D., Lacivita, E., Saso, L., Leopoldo, M., Laviola, G., 2012. Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice. Neuropharmacology 62, 833-842.
3. Alvarez, E., Perez, V., Dragheim, M., Loft, H., Artigas, F., 2012. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 15, 589-600.
4. Areberg, J., Luntang-Jensen, M., Sogaard, B., Nilausen, D.O., 2012. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin. Pharmacol. Toxicol. 110, 401-404.
5. Artigas, F., 2013. Serotonin receptors involved in antidepressant effects. Pharmacol. Ther. 137, 119-131.
6. Bang-Andersen, B., Ruhland, T., Jorgensen, M., Smith, G., Frederiksen, K., Jensen, K.G., Zhong, H., Nielsen, S.M., Hogg, S., Mork, A., Stensbol, T.B., 2011. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 54, 3206-3221.
7. Bartolini, L., Casamenti, F., Pepeu, G., 1996. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Pharmacol. Biochem. Behav. 53, 277-283.
8. Bertaina-Anglade, V., Drieu-La-Rochelle, C., Mocaer, E., Seguin, L., 2011. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol. Biochem. Behav. 98, 511-517.
9. Bonaventure, P., Kelly, L., Aluisio, L., Shelton, J., Lord, B., Galici, R., Miller, K., Atack, J., Lovenberg, T.W., Dugovic, C., 2007. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J. Pharmacol. Exp. Ther. 321, 690-698.
10. Bosker, F.J., Folgering, J.H., Gladkevich, A.V., Schmidt, A., van der Hart, M.C., Sprouse, J., den Boer, J.A., Westerink, B.H., Cremers, T.I., 2009. Antagonism of 5-HT(1A) receptors uncovers an excitatory effect of SSRIs on 5-HT neuronal activity, an action probably mediated by 5-HT(7) receptors. J. Neurochem. 108, 1126-1135.
11. Cowen, P., Sherwood, A.C., 2013. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J. Psychopharmacol. 27, 575-583.
12. Dallaspezia, S., Benedetti, F., 2011. Chronobiological therapy for mood disorders. Expert Rev. Neurother. 11, 961-970.
13. Di Pilato, P., Niso, M., Adriani, W., Romano, E., Travaglini, D., Berardi, F., Colabufo, N.A., Perrone, R., Laviola, G., Lacivita, E., Leopoldo, M., 2014. Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. Rev. Neurosci. 25, 401-415.
14. Duncan Jr., W.C., 1996. Circadian rhythms and the pharmacology of affective illness. Pharmacol. Ther. 71, 253-312.
15. 7 receptors in the suprachiasmatic nucleus. J. Neurosci. 21, 5351-5357.
16. 7 receptor crosstalk in the regulation of emotional memory: implications for effects of selective serotonin reuptake inhibitors. Neuropharmacology 63, 1150-1160.
17. 7 receptor: effect on object recognition performances in mice. Psychopharmacol. Berl. 231, 393-400.
18. 7 receptors and cognition. Rev. Neurosci. 25, 311-323.
19. Graff, C., Challet, E., Pevet, P., Wollnik, F., 2007. 5-HT3 receptor-mediated photiclike responses of the circadian clock in the rat. Neuropharmacology 52, 662-671.
20. Hagan, J.J., Price, G.W., Jeffrey, P., Deeks, N.J., Stean, T., Piper, D., Smith, M.I., Upton, N., Medhurst, A.D., Middlemiss, D.N., Riley, G.J., Lovell, P.J., Bromidge, S.M., Thomas, D.R., 2000. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br. J. Pharmacol. 130, 539-548.
21. Häggström, L., Nielsen, R.Z., Danchenko, N., Poulsen, L., 2013. A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. Eur. Neuropsychopharmacol. 23, S412.
22. Healy, D., Waterhouse, J.M., 1995. The circadian system and the therapeutics of the affective disorders. Pharmacol. Ther. 65, 241-263.
23. 7 receptor and disorders of the nervous system: an overview. Psychopharmacol. Berl. 206, 345-354.
24. 7 receptor research. Trends Pharmacol. Sci. 25, 481-486.
25. Katona, C., Hansen, T., Olsen, C.K., 2012. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 27, 215-223.
26. Lanfumey, L., Mongeau, R., Hamon, M., 2013. Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol. Ther. 138, 176-184.
27. Leiser, S.C., Pehrson, A.L., Robichaud, P.J., Sanchez, C., 2014. The multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine - a quantitative electroencephalographic study in the rat. Br. J. Pharmacol. 171, 4255-4272.
28. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 11, 449-458.
29. McIntyre, R.S., Lophaven, S., Olsen, C.K., 2013. Randomized, double-blind, placebo-controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). Neuropsychopharmacology 38, S380-S381.
30. 7 receptors, novel alternative. Rev. Neurosci. 25, 325-356.
31. Mork, A., Montezinho, L.P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., Gulinello, M., Sanchez, C., 2013. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol. Biochem. Behav. 105, 41-50.
32. Mork, A., Pehrson, A., Brennum, L.T., Nielsen, S.M., Zhong, H., Lassen, A.B., Miller, S., Westrich, L., Boyle, N.J., Sanchez, C., Fischer, C.W., Liebenberg, N., Wegener, G., Bundgaard, C., Hogg, S., Bang-Andersen, B., Stensbol, T.B., 2012. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J. Pharmacol. Exp. Ther. 340, 666-675.
33. 7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 21, 352-367.
34. Murphy, D.L., Andrews, A.M., Wichems, C.H., Li, Q., Tohda, M., Greenberg, B., 1998. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J. Clin. Psychiatry 59 (Suppl. 15), 4-12.
35. Pickard, G.E., Smith, B.N., Belenky, M., Rea, M.A., Dudek, F.E., Sollars, P.J., 1999. 5-HT1B receptor-mediated presynaptic inhibition of retinal input to the suprachiasmatic nucleus. J. Neurosci. 19, 4034-4045.
36. Roca, A.L., Weaver, D.R., Reppert, S.M., 1993. Serotonin receptor gene expression in the rat suprachiasmatic nuclei. Brain Res. 608, 159-165.
37. Roenneberg, T., Chua, E.J., Bernardo, R., Mendoza, E., 2008. Modelling biological rhythms. Curr. Biol. 18, R826-R835.
38. 7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology 46, 52-62.
39. Stenkrona, P., Halldin, C., Lundberg, J., 2013. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur. Neuropsychopharmacol. 23, 1190-1198.
40. Tardito, D., Molteni, R., Popoli, M., Racagni, G., 2012. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur. Neuropsychopharmacol. 22 (Suppl. 3), S482-S486.
41. 7 Receptor Agonists for the Treatment of Pain. International application published under the patent cooperation treaty (PCT) WO 2008/000495 A1 2008.
42. Westrich, L., Pehrson, A., Zhong, H., Nielsen, S.M., Frederiksen, K., Stensbol, T.B., Boyle, N.J., Hentzer, M., Sanchez, C., 2012. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int. J. Psychiatry Clin. Pract. 5 (Suppl. 1), 47.
43. 7 receptor blockade on circadian rhythm regulation in rodents. Physiol. Behav. 110-111, 42-50.
44. Wirz-Justice, A., 2003. Chronobiology and mood disorders. Dialogues Clin. Neurosci. 5, 315-325.
45. Wirz-Justice, A., 2006. Biological rhythm disturbances in mood disorders. Int. Clin. Psychopharmacol. 21 (Suppl. 1), S11-S15.
46. Yoo, S.H., Yamazaki, S., Lowrey, P.L., Shimomura, K., Ko, C.H., Buhr, E.D., Siepka, S.M., Hong, H.K., Oh, W.J., Yoo, O.J., Menaker, M., Takahashi, J.S., 2004. PERIOD2:: LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc. Natl. Acad. Sci. U. S. A. 101, 5339-5346.
47. Yu, E.A., Weaver, D.R., 2011. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging (Albany N. Y.) 3, 479-493.